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a  b  s  t  r  a  c  t
Longer  survival  after  corrective  surgery  for  congenital  heart  diseases  has  rendered  late  complications
more  important.  One  of  these  complications  is aortic  dilatation  which  may  occur  in  patients  with  repaired
or unrepaired  disease  and can  progress  to aneurysm,  dissection,  and  rupture.  This aortic  dilatation  in
various congenital  heart  diseases  does  not  simply  mean  anatomical  dilatation  of the  aortic  root,  but  it
closely relates  to the  aortic  pathophysiological  abnormality,  aortic  regurgitation,  and  aortic  and  ventri-eywords:
ortic diseases
ortic regurgitation
ortic dissection
ongenital heart defects
arfan syndrome
cular  dysfunction;  therefore,  we  can  recognize  this  complex  lesion  as  a  new  concept:  “aortopathy”.  The
pathophysiology  of  this  disease  is complex  and  only  partially  understood.
In  this  review,  we  ﬁrst  discuss  history,  pathophysiology,  and  clinical  features  of  aortic  dilatation  and
aortopathy  of  congenital  heart  disease.  Then  we provide  a review  of  the  evaluation  and  management  of
this disease.urner syndrome ©  2012  Japanese  College  of Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
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ntroduction
In repaired or unrepaired congenital heart disease (CHD), we
ften observe aortic dilation, aneurysm, and valvular regurgitation
AR). Longer survival after corrective surgery for CHD has rendered
ate complications like these more obvious and clinically important.
everal reports have revealed that in these patients, dilated aorta is
ssociated with decreased elasticity and increased stiffness of the
ortic wall, negatively inﬂuencing the systemic ventricular systolic
nd diastolic functions due to increased afterload and ventricu-
ar hypertrophy [1,2]. Aortic dilation in known genetic syndromes
Marfan, Turner, Loeys–Dietz, and Ehler–Danlos syndromes) and
ongenital aortic diseases [bicuspid aortic valve (BAV), and coarc-
ation of aorta (COA)] is well recognized. However, aortic dilation
n other CHDs has gained attention more recently. In this review,
e will discuss the aortic complications of CHD, emphasizing their
istory, pathophysiology, evaluation, and management.
istory
Congenitally BAV was the ﬁrst non-syndromic CHD in which
ortic dissection and dilation were reported [3].  Aortic dissection
as found to be 9 times more prevalent in BAV patients than
n those with tricuspid valves and occurred at an earlier age (55
ersus 63 years) [4].  Aortic dilation begins during childhood in BAV
atients, regardless of the presence of aortic stenosis or AR [5]. His-
ologic abnormalities in the ascending aorta in BAV patients are
imilar to those found in Marfan patients, including the so-called
ystic medial necrosis, elastic fragmentation, and smooth muscle
ell orientation [6,7]. Cystic medial necrosis was unequivocally seen
n the pre- and post-coarctation segments of patients with COA [8].
mong the cyanotic CHD, tetralogy of Fallot (TOF) was the ﬁrst in
hich aortic dilation was recognized [9,10].
HD associated with aortic dilatation
ortic dilatation of TOF and its variants
Aortic dilatation of TOF and its variants [pulmonary atresia with
entricular septal defect (PA-VSD) and double-outlet right ventri-
le with VSD and pulmonary stenosis (PS)], is the most studied in
 cyanotic CHD. This complication can be seen before corrective
urgery or thereafter, and can be progressive even after the opera-
ion [2].  Chong et al. reported annular and sinus dilations in 88% and
able 1
eported ascending aortic large aneurysms, dissection, and ruptures (secondary patholog
Number of patients Sex 
Niwa et al. [17] 1 F 
Dearani et al. [13] 1 ? 
Cleuziou et al. [12] 1 M
Kim  et al. [15] 1 M 
Roux  et al. [20] 1 M 
Rathi  et al. [19] 1 M 
Konstantinov et al. [16] 1 M 
Ramayya et al. [18] 1 M 
Egan  et al. [14] 1 M 
Stulak  et al. [21] 20 ? 
, female; M,  male; PA, pulmonary atresia; VSD, ventricular septal defect; DORV, doub
ypoplastic left heart syndrome. .  . .  .  . . . . . .  .  . .  . . .  .  .  . . . . . .  . . . . . . .  .  . .  . . . . .  . . . . . . .  .  .  .  . .  .  . . . . . .  .  .  . .  . . .  .  . .  . . .  .  .  . 20
87% of their patients, respectively. The only signiﬁcant determinant
of dilation was the duration of follow up [2].  In the series of Niwa
et al., 15% of repaired TOF adults had a dilated aortic root. Progres-
sive aortic dilation was  signiﬁcantly related to male sex, PA versus
PS, longer time interval between palliative shunt and total repair,
and right aortic arch [11]. Bhat et al. found that aortic dimensions
normalize by the age of 7 years if TOF was  repaired in infancy, while
they remain higher than normal in case of later repair [42].
Different from the Marfan syndrome, aortic aneurysm and dis-
section/rupture were rarely reported (Table 1) [12–21],  mostly in
TOF or its variants. This suggests that aortopathy of TOF may  be less
dangerous than those of Marfan syndrome, COA, or BAV.
Neo-aortic dilation after arterial switch operation
Aortic dilation and AR are known complications of arterial
switch operation (ASO) [22,23]. Losay et al. found AR in 14.9% of
ASO patients after a mean follow-up duration of 76 months [24].
They showed that presence of VSD or Taussig–Bing anomaly, prior
pulmonary artery banding (PAB), anomalies of the aortic arch, older
age at ASO, and discrepancy between the great arteries sizes can
be risk factors for late AR [24]. Schwartz et al. reported freedom
from aortic dilation, AR, and root or valve surgery 10 years after
ASO to be 51%, 93%, and 95%, respectively [25]. Previous PAB was
the risk factor for aortic dilation while older age at ASO, presence
of VSD, and previous PAB were the risk factors for AR [25]. Hutter
et al. found aortic dilation without any progressive change dur-
ing the follow up except at sinutubular junction during the ﬁrst
1–2 years after ASO [26]. The risk factors were the presence of VSD,
Taussig–Bing anomaly, COA, PAB, and age at ASO [26]. In 28 patients
after one-stage ASO at the age of 4–42 days, cystic medial necrosis
was observed in both aorta and the pulmonary artery in 20% [27].
Hypoplastic left heart syndrome
Aortic dilation can be seen in patients with hypoplastic left heart
syndrome. Cohen et al. reported AR and aortic dilation in 61% and
98% of their cohort, respectively. AR was  the only risk factor for
aortic dilation [28]. When pulmonary autograft is used for the aor-
tic root replacement, lesser support by the thin right ventricular
myocardium [in contrast to the supports from thick left ventri-
cular (LV) myocardium and wedging between the atrioventricular
valves for the aorta] makes it vulnerable to dilation [28,29]. In addi-
tion, mild pulmonary regurgitation can be physiologically seen in
y) in patients with congenital heart disease (primary pathology).
Primary pathology Secondary pathology
Eisenmenger VSD Rupture
PA-VSD Dissection
DORV-VSD-PS Aneurysm
TOF Dissection
TOF Aneurysm
TOF Dissection
TOF Dissection
TOF Aneurysm
HLHS Dissection
Conotruncal 19 aneurysms, 1 dissection
le-outlet right ventricle; PS, pulmonary stenosis; TOF, tetralogy of Fallot; HLHS,
1 al of C
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p8 K.S. Zanjani, K. Niwa / Journ
ormal subjects while any degree of AR is considered abnormal
30,31].
fter the Ross operation
To this list, dilation of the pulmonary autograft and neo-AR after
he Ross operation can be added [32–38].  Annular and sinus dilata-
ions occur mainly in the ﬁrst year after this operation. Elkins et al.
bserved that grade 2 baseline AR, BAV, a history of COA, and repair
f an aortic aneurysm as part of a Ross operation were associated
ith a more rapid dilation during the ﬁrst year after the opera-
ion [33]. They also showed that the predicted probability of no
r trivial AR decreased from 63% in the early postoperative period
o 24% after 16 years [33]. In the report of David et al., aortic root
eplacement was  the only risk factor for sinus dilation [32]. The
ost common cause for the failure of Ross operation is probably
ulmonary autograft dilation [32].
runcus arteriosus
Carlo et al. found dilated aortic root in the majority of operated
runcus arteriosus patients (73 of 76 in their cohort) [39]. How-
ver, only 6 patients needed repeat surgical intervention for aortic
ilation and none had dissection or rupture [39].
ther CHD
Aortic dilation was rarely seen in patients with single ventricle
nd PS, and Eisenmenger syndrome [17].
In the literature, reported cases of aortic aneurysm, rupture, or
issection after CHD other than TOF and its variants are extremely
are (Table 1). Therefore, other CHD aortopathies seem to be even
ess severe in pathological nature.
athophysiology
Several studies showed that intrinsic aortic wall abnormalities,
ortic overﬂow, and genetic alterations contribute to the devel-
pment of aortic dilatation in CHD [2,11,17,40,41].  Niwa et al.
bserved that aortic medial histopathological abnormalities exist
n patients with various CHD [17]. These aortic wall abnormali-
ies resemble those in patients with Marfan syndrome but to a
ilder degree. Tan et al. examined aortic histology of TOF patients
or medionecrosis, ﬁbrosis, cystic medial necrosis, and elastic frag-
entation, comparing them with normal subjects. They found
igher histologic grading scores in TOF patients and a signiﬁcant
orrelation with ascending aortic circumference to LV index [41].
howdhury et al. studied the histopathology of aorta, ﬁnding sig-
iﬁcant lamellar loss and abnormal histopathology in 78% and 96%
f their cohort, respectively [40].
Evidence for the role of aortic overﬂow over time includes the
ssociations of higher age at operation, PA versus PS, and longer
resence of surgical aortopulmonary shunts with aortic dilation
2,11,42]. Bhat et al. observed a signiﬁcant 12% increase in mean
ortic diameter after surgical aortopulmonary shunts [42]. TOF
atients with aortic dilation have signiﬁcantly longer surgical aor-
opulmonary shunts to corrective surgery interval than those with
ormal aorta (12 ± 8.3 years versus 8 ± 6.1 years) [11].
Chowdhury et al. investigated the presence of ﬁbrillin-1 gene
olymorphisms or mutations in TOF patients with dilated aorta,
nding 50.9% prevalence of DNA sequence variants in these patients
nd >8 times risk of aortic dilation in the presence of these vari-
nts [40]. In a cohort of 93 patients with 22q11.2 deletion without
onotruncal abnormality, John et al. found aortic dilation in 10
atients [43].ardiology 61 (2013) 16–21
AR in unrepaired TOF patients may  be due to annular dilation,
weaker support of the right coronary cusp by the deﬁcient outﬂow
septum, and cusp prolapse [2,10,42]. Only in a small number of
patients can surgical trauma potentiate AR. Bhat et al. showed that
the frequency and degree of AR can be higher in case of late TOF
repair [42].
In CHD patients, the aortic abnormalities are not limited to
dilation and AR. Decreased aortic distensibility derived from
increased pulse wave velocity [1,44],  greater carotid augmentation
index [44], decreased aortic distensibility [2,45],  increased stiff-
ness index [2,46],  reduced aortic strain [2],  and higher impedance
and increased LV pulsatile load [1] were found in patients after
ASO and TOF repair. This aortic stiffness has many negative con-
sequences, including increased pulsatile load on LV and decreased
cardiac output [1],  decreased coronary blood ﬂow and abnormal
coronary ﬂow pattern [45,47], aortic dilation, and AR [1,44,48].
The mechanism of AR development maybe the transmission of
unnatural fatigue stresses to the leaﬂets by the rigid aortic root
[45]. Murakami et al. suggested three mechanisms for neoaortic
stiffness after ASO: manipulations during the operation (suturing
of the coronary bottoms), characteristics of the pulmonary artery
(different muscle ﬁber composition) [49], and damage to the vasa
vasorum [45].
We  can recognize this complex lesion of aortic dilation, AR,
aortic pathophysiological abnormality, and aortic and ventricular
dysfunctions as a new concept: “aortopathy”. The exact cause of
aortopathy is unknown at this point in time; it may  be an intrin-
sic abnormality or increased aortic blood ﬂow, or most probably a
combination of them.
Evaluation
Diagnostic tools
Echocardiography, either transthoracic or transesophageal, is
the routine method of aortic evaluation (dimensions, AR detection
and grading, and assessment of ventricular systolic and diastolic
functions). Computed tomography scan or magnetic resonance
imaging (Fig. 1) can be indicated when echocardiographic views
are poor or when aortic root surgery is anticipated, for precise mea-
surements and planning repeat median sternotomy. Angiography
is rarely used.
Measurement
Chong et al. observed that aortic annulus and sinuses of Val-
salva were enlarged in a higher percentage of their TOF cohort than
sinotubular junction and ascending aorta [2].  Measuring the diame-
ter in systole or diastole, and including the aortic thickness mostly
depend on the reference values used for the evaluation of aortic
diameters [50].
Parameters
Absolute values are commonly used for decision making in
adults, especially for surgery. Dearani et al. presented detailed rec-
ommendations for the absolute aortic sizes and indications for
aortic root surgery in patients with aortic dilation [13]. Z values are
used for deﬁning and following up aortic dilation in CHD aortopa-
thy. Marino et al. used Z value to ﬁnd patients with aortic dilation
after ASO (threshold ≥2) [23]. Chong et al. set a Z score >2 as the def-
inition of aortic dilation in their cohort of TOF patients [2].  However,
John et al. used values >2.5 for the same purpose in patients with
22q11.2 deletion [43]. Z scores >2.5 are unequivocally abnormal,
while those <2 can be considered normal. Values between 2 and 2.5
are borderline. Observed to expected values ratio was mostly used
K.S. Zanjani, K. Niwa / Journal of Cardiology 61 (2013) 16–21 19
F ital he
d aired
i
[
f
t
o
a
u
M
F
y
n
r
D
d
r
s
a
a
a
b
b
T
p
m
M
t
t
t
m
r
l
t
P
wig. 1. Computed tomography angiographies of patients with aortopathy of congen
efect.  The ascending aorta is dilated (>48 mm)  and (B) a 6-year-old girl with unrep
n research for monitoring aortic root dimensions through time
51,52]. Niwa et al. deﬁned aortic dilation when this ratio was  >1.5,
ound in 15% of their patients [11]. Chowdhury et al. used the same
hreshold for distinguishing TOF patients with dilated aorta (68.9%
f their cohort) [40]. Values indexed to the patient’s body surface
rea [11] and ascending to descending aortic diameters ratio were
sed less often [53,54].
anagement
ollow up
Due to the progressive nature of aortic dilation [11], at least
early follow ups are recommended. Closer follow ups may  be
ecessary when the aortic diameter reaches surgical thresholds or
apidly changes (≥0.5 cm/year), similar to the Marfan patients [50].
rugs
Beta blockers are recommended for the prevention of aortic
ilation in the Marfan syndrome when the diameters have not
eached the surgical thresholds [50], although there are controver-
ies regarding their effect [55]. Their mode of action is controversial
s well. They might exert their action through negative inotropic
nd chronotropic actions, decreasing ascending aorta shear stress
nd changing the rate of pressure changes over time (dP/dT)  [56].
Angiotensin-converting enzyme inhibitors and calcium channel
lockers were also recommended for this purpose in cases of beta
locker’s failure or intolerance, or a combination of both [50,57].
he afterload reducing capability of these drugs can be helpful in
atients with concomitant AR.
Angiotensin receptor blockers showed promising results in a
ouse model of Marfan syndrome and then in a small cohort of
arfan patients [57,58]. They antagonize transforming growth fac-
or  whose excessive signaling may  cause aortic root dilation in
he Marfan syndrome [57]. Several large clinical trials are underway
o conﬁrm the beneﬁcial effects of these drugs [59,60].
There is no evidence about the usefulness of the above-
entioned drugs in CHD aortopathy. Due to the histopathological
esemblance of CHD aortopathy to the Marfan syndrome, it may  be
ogical to administer these drugs to the CHD patients with aortopa-
hy until the availability of more speciﬁc data.regnancy
Neither increased maternal death nor aortic complication
as observed in the reports of pregnancies in repaired CHDart disease. (A) A 14-year-old patient with pulmonary atresia and ventricular septal
 persistent truncus arteriosus and dilated ascending aorta (>43 mm).
[61–64].  Veldtman et al. reported 112 pregnancies in 42 corrected
TOF patients [64]. There was  no signiﬁcant difference in aortic
diameter between the patients with a history of pregnancy and
those without (35 ± 6 mm versus 35 ± 10 mm)  [64]. A system-
atic review of the outcome of 2491 pregnancies in women  with
CHD by Drenthen et al. revealed no aortic complication [61]. The
above evidence shows that pregnancy in repaired CHD is seldom
associated with aortic complications, in contrast to the Marfan
syndrome.
Aortopulmonary shunts
Minor aortopulmonary collateral arteries may  be left open after
surgical repair of CHD, especially PA-VSD. These arteries increase
aortic ﬂow and theoretically may contribute to the aortic dilation
[11]. In a small cohort of Marfan patients, it was shown that closure
of even small patent ductus arteriosus may  negatively affect aortic
dimensions in at least some Marfan patients [52]. Although there is
no direct evidence for this recommendation, occlusion of residual
collateral arteries seems to be prudent in these patients with aortic
dilation.
Sport/exercise
There are no speciﬁc recommendations for sport participation
of patients with CHD aortopathy. The 36th Bethesda Confer-
ence proposed recommendations for athletes with cardiovascular
abnormalities [65]. There are speciﬁc recommendations for the
patients with Marfan syndrome, BAV, AR, and CHD [66–68].  A com-
bination of these recommendations can be applied for the CHD
patients with aortopathy. Table 2 summarizes the recommenda-
tions for the patients with Marfan syndrome, BAV, AR, and repaired
TOF (as the prototype of CHD associated with aortopathy). The rec-
ommendations for the other CHD can be found in Task Force 2 [67].
Surgical management
As there is an excellent review by Dearani et al. about the surgi-
cal management of CHD aortopathy, this subject was not discussed
here [13].
Other measuresHypertension is a well-known risk factor of aortic dilation in
adults. Screening of CHD patients with aortopathy and treating
even mild hypertension may  be prudent [71]. Avoiding obesity and
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Table 2
The recommendations of the 36th Bethesda Conference for athletes with BAV, Marfan syndrome, AR, and repaired TOF.
Conditions Recommendations
BAV [66] Normal aortic dimensions (<40 mm in adults, Z < 2 in children),
no AS and no AR
All competitive sports
Dilated aortic root (40–45 mm)  Low and moderate static or low and moderate dynamic competitive
sports (classes IA, IB, IIA, and IIB)
No sport with the potential of body collision or trauma
Dilated aortic roots (>45 mm)  Low-intensity competitive sports only (class IA)
Marfan  syndrome [68] Normal aortic dimensions (<40 mm in adults, Z < 2 in children),
not more than mild MR, and no family history of dissection or
SD  in a Marfan relative
Low and moderate static/low dynamic competitive sports (classes IA
and  IIA)
Aortic dilation (≥40 mm in adults, Z ≥ 2 in children), prior
surgical aortic root reconstruction, chronic dissection of aorta
or  other artery, moderate to severe MR,  or family history of
dissection or SD
Low-intensity competitive sports only (class IA)
All No sport with the potential of body collision
AR  [66] Mild to moderate and normal or mildly increased LVEDD
(athletic training)
All competitive sports
Moderate LV enlargement (LVEDD 60–65 mm)  and no
symptoms or ventricular arrhythmias during exercise test
Low and moderate static and low, moderate, and high dynamic
competitive sports (classes IA, IB, 1C, IIA, IIB, and IIC)
Ventricular arrhythmias See Task Force 7 [69]
Moderate AR and symptoms No competitive sport
Severe LV enlargement (LVEDD > 65 mm)  No competitive sport
AR  and signiﬁcant aortic dilation (>45 mm)  not a Marfan
patient
Low-intensity competitive sports only (class IA)
Repaired TOF [67] Normal or near-normal RV pressure, no or only mild RV
volume overload, no signiﬁcant residual shunt, and no atrial or
ventricular arrhythmia
All competitive sports
Pulmonary regurgitation and RV volume overload, residual RV
hypertension (peak systolic pressure ≥50% systemic pressure),
or  atrial or ventricular arrhythmias
Low-intensity competitive sports only (class IA)
BAV, bicuspid aortic valve; AR, aortic regurgitation; TOF, tetralogy of Fallot; AS, aortic stenosis; MR,  mitral regurgitation; SD, sudden death; LVEDD, left-ventricular end-
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or the deﬁnition of sport classes please refer to the Task Force 8 [70].
moking, and adhering to a healthy diet are recommended for the
arfan patients [72], as well as for those with CHD aortopathy.
onclusions
Although less serious than in the Marfan syndrome, aortopa-
hy in repaired or unrepaired CHD is not a benign disease. The
athophysiology is complex and not well understood.
Routine follow up of these patients and special attention to aor-
ic root measurement are necessary. Absolute aortic dimensions
nd their Z values are mostly used for decision making. There is
o evidence about the usefulness of drugs to prevent aortic dila-
ion. Pregnancy is generally well tolerated in these patients. Speciﬁc
ecommendations for sport and exercise do not exist; however,
 combination of recommendations for similar situations can be
sed.
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